Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Short-term Investments (2018 - 2022)

Spero Therapeutics' Short-term Investments history spans 5 years, with the latest figure at $49.9 million for Q1 2022.

  • For Q1 2022, Short-term Investments rose 29.04% year-over-year to $49.9 million; the TTM value through Mar 2022 reached $49.9 million, up 29.04%, while the annual FY2021 figure was $33.8 million, 18.9% down from the prior year.
  • Short-term Investments reached $49.9 million in Q1 2022 per SPRO's latest filing, up from $33.8 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $90.7 million in Q3 2018 to a low of $2.0 million in Q3 2020.
  • Average Short-term Investments over 5 years is $37.5 million, with a median of $33.8 million recorded in 2021.
  • Peak YoY movement for Short-term Investments: tumbled 95.85% in 2020, then soared 427.37% in 2021.
  • A 5-year view of Short-term Investments shows it stood at $81.4 million in 2018, then crashed by 35.7% to $52.3 million in 2019, then fell by 20.3% to $41.7 million in 2020, then fell by 18.9% to $33.8 million in 2021, then soared by 47.42% to $49.9 million in 2022.
  • Per Business Quant, the three most recent readings for SPRO's Short-term Investments are $49.9 million (Q1 2022), $33.8 million (Q4 2021), and $10.6 million (Q3 2021).